Roivant Sciences/$ROIV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Ticker

$ROIV
Sector
Primary listing

Employees

750

Roivant Sciences Metrics

BasicAdvanced
$11B
-
-$0.69
1.15
-

What the Analysts think about Roivant Sciences

Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.

Bulls say / Bears say

Roivant held $4.9 billion in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025, giving the company a solid liquidity runway towards profitability despite ongoing R&D investment (GlobeNewswire)
The company repurchased $1.3 billion of its shares by March 31, 2025—a 14% reduction in outstanding shares—and completed a $1.5 billion repurchase by June 30, 2025, launching an additional $500 million buyback program. This demonstrates disciplined capital allocation and support for EPS (GlobeNewswire; GlobeNewswire)
The VALOR Phase 3 study of brepocitinib in dermatomyositis is fully enrolled with topline data expected in the second half of 2025, and new registrational trials for IMVT-1402 in Graves' disease and Sjögren’s disease were started in June 2025, providing near-term clinical catalysts (GlobeNewswire; GlobeNewswire)
Q1 FY26 revenue dropped to $2.17 million from $7.99 million a year earlier, highlighting limited commercial-stage revenue diversity and a heavy dependence on near-term clinical milestones (GlobeNewswire)
For the fiscal year ended March 31, 2025, R&D expenses climbed by $110.5 million to $550.4 million and G&A expenses rose by $175.3 million—mainly due to share-based compensation—resulting in a $729.8 million loss from continuing operations, showing aggressive cash burn and growing operational losses (GlobeNewswire)
The expansion of LNP patent litigation against Moderna into international jurisdictions such as Canada, Japan, Switzerland, and the UPC, with summary judgment and jury trial phases ongoing into 2026, creates a legal overhang and possible significant litigation costs (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

Roivant Sciences Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Roivant Sciences Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ROIV

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs